Although Rac and its activator Tiam1 are known to stimulate cell-cell adhesion, the mechanisms regulating their activity in cell-cell junction formation are poorly understood. Here, we identify β2-syntrophin as a Tiam1 interactor required for optimal cell-cell adhesion. We show that during tight-junction (TJ) assembly β2-syntrophin promotes Tiam1-Rac activity, in contrast to the function of the apical determinant Par-3 whose inhibition of Tiam1-Rac activity is necessary for TJ assembly. We further demonstrate that β2-syntrophin localizes more basally than Par-3 at cell-cell junctions, thus generating an apicobasal Rac activity gradient at developing cell-cell junctions. Targeting active Rac to TJs shows that this gradient is required for optimal TJ assembly and apical lumen formation. Consistently, β2-syntrophin depletion perturbs Tiam1 and Rac localization at cell-cell junctions and causes defects in apical lumen formation. We conclude that β2-syntrophin and Par-3 fine-tune Rac activity along cell-cell junctions controlling TJ assembly and the establishment of apicobasal polarity.
Co-precipitated endogenous syntrophin was detected by immunoblotting with anti-syntrophin antibody. (i) Tiam1-HA was immunoprecipitated from MDCKII cells that were also engineered to express shRNA targeting β2-syntrophin (β2-syntrophin RNAi#1) following the addition of doxycycline (+Dox). Co-precipitated endogenous syntrophin and utrophin were detected by immunoblotting. All data shown are representative of at least three independent experiments. IP, immunoprecipitation. Uncropped images of blots are shown in Supplementary Fig. S9 .
cell-cell adhesions was unknown. We reasoned that this complex could be important for the function of Tiam1 at cell-cell adhesions. We performed co-immunoprecipitations to validate the mass spectrometry results. We found that exogenous Tiam1 co-precipitates endogenous syntrophin and utrophin from HEK293T cells (Fig. 1a) . Moreover, endogenous Tiam1 co-precipitated endogenous syntrophin (Fig. 1b) , and Tiam1 and β2-syntrophin co-localized at cell-cell adhesions in MDCKII cells (Fig. 1c) . We next defined their interaction domains using amino-terminally truncated Tiam1-HA constructs and GFPtagged β2-syntrophin domain constructs 25 ( Fig. 1d,e) . We found that the carboxy-terminal 196 amino acids of Tiam1 (C196-Tiam1) and the PDZ domain of β2-syntrophin were sufficient for the interaction ( Fig. 1f and Supplementary Fig. S1a,b) . C196-Tiam1 contains the internal sequence KETDI matching the consensus syntrophin PDZ-binding motif (PBM), K/R-E-(S/T)-X-(V/L/I/M) (ref. 26 ; Fig. 1d and Supplementary Fig. S1c ). Deletion of KETDI from C196-Tiam1 (Fig. 1f) , and from full-length Tiam1 (Fig. 1g) , abolished the interaction with β2-syntrophin, despite there being other sequences in Tiam1 matching the consensus syntrophin PBM ( Supplementary  Fig. S1c ). Two short Tiam1 fragments containing KETDI (KETDI-19 and KETDI-27) did not bind or bound only weakly to β2-syntrophin, whereas a longer fragment (KETDI-44) did interact ( Fig. 1h and Supplementary Fig. S1d ), suggesting that the interaction requires residues flanking KETDI. Furthermore, KETDI was required for the Tiam1-utrophin interaction (Fig. 1g ) and β2-syntrophin knockdown abolished the Tiam1-utrophin interaction (Fig. 1i) , suggesting that Tiam1 interacts with utrophin indirectly through β2-syntrophin. The KETDI sequence is highly conserved in Tiam1 orthologues ( Supplementary Fig. S1e ), indicating the importance of the interaction for Tiam1 function. Notably, this sequence is found in Tiam2 (Stef; Supplementary Fig. S1e ).
β2-syntrophin regulates TJ assembly
We next investigated whether β2-syntrophin regulates cell-cell adhesion similarly to Tiam1 (refs 8-13) . For this we engineered MDCKII cells with doxycycline-inducible expression of short hairpin RNA (shRNA) sequences targeting β2-syntrophin and a nontargeting control (Fig. 2a,b) . Calcium withdrawal disassembles cell-cell adhesions, which is reversed by calcium readdition 27 (calcium switch, CS). The remodelling of junctional complexes following CS mimics events accompanying epithelial cell movements during wound closure and tumour development. TJ integrity can be assessed by measuring the transepithelial electrical resistance (TER) of cell monolayers grown on Transwell filters and together with immunostaining for TJ markers has been widely used to identify TJ assembly regulators 8, 10, 28, 29 . We found that β2-syntrophin knockdown in MDCKII cells markedly retards CSinduced TER development, indicating defective TJ assembly (Fig. 2c) . We confirmed that the TER defect was β2-syntrophin-dependent by rescuing with expression of shRNA-resistant β2-syntrophin (Fig. 2d,e) . Immunofluorescence microscopy for the TJ marker occludin after CS confirmed a delay in TJ assembly (Fig. 2f) . We also observed delayed TJ assembly after plating (Fig. 2g,h ), confirming that the defects are not CS-specific. Immunostaining for β-catenin revealed impaired AJ assembly in β2-syntrophin knockdown cells ( Supplementary Fig. S2a ). It is possible that the TJ assembly defects result from defective AJ formation. By performing hanging-drop assays to assess the aggregation ability of single cells, we also found that β2-syntrophin knockdown impedes cell-cell aggregation ( Supplementary Fig. S2b,c) . Moreover, a cell-dissociation assay demonstrated that β2-syntrophin knockdown compromises cell-cell adhesion strength ( Supplementary Fig. S2d ).
Together, these results demonstrate that β2-syntrophin regulates epithelial cell-cell adhesions.
Tiam1-induced Rac activity impedes TJ assembly
To relate β2-syntrophin function at cell-cell adhesions to its Tiam1 interaction, we further interrogated Tiam1 function in TJ assembly, because previous studies are conflicting [8] [9] [10] . We found that doxycycline-inducible Tiam1 knockdown in MDCKII cells for either a short or long period did not inhibit CS-induced TER development, but slightly enhanced it ( Fig. 3a-d ). Tiam1 knockdown with an alternative shRNA did not alter TER, probably owing to less-efficient knockdown ( Supplementary Fig. S3a-d) . We next found that Tiam1-HA-WT overexpression retarded CS-induced TER development (Fig. 3e) . Immunostaining for occludin (Fig. 3f) and quantifying the number of intact junctions (Fig. 3g) confirmed delayed TJ assembly. To investigate whether this was through Rac activation, we analysed the effect of overexpressing dominant-negative/GEF-dead Tiam1 (Tiam1-HA-DH*) at levels comparable to Tiam1-HA-WT ( Supplementary Fig. S3e ). Tiam1-HA-DH* expression enhanced CS-induced TER development (Fig. 3h ) consistent with our Tiam1 knockdown data. Immunostaining for occludin at 15 min following CS (Fig. 3i) and quantifying the number of intact junctions (Fig. 3j) confirmed accelerated TJ assembly. Collectively, these results show that Tiam1-induced Rac activity impedes TJ assembly in MDCKII cells, consistent with the findings of ref. 8. β2-syntrophin promotes Tiam1-Rac activity during TJ assembly We next investigated whether the ability of overexpressed Tiam1 to inhibit TJ assembly requires its interaction with β2-syntrophin. Expression of Tiam1-HA-KETDI at levels comparable to Tiam1-HA-WT ( Supplementary Fig. S4a ) had little effect on CS-induced TER development (Fig. 4a) . Likewise, no significant change in TJ assembly was observed following immunostaining for occludin (Fig. 4b) and quantification of intact junctions (Fig. 4c) . As the inhibition of TJ assembly by overexpressed Tiam1 requires its Rac-GEF activity (Fig. 3h-j) , we reasoned that β2-syntrophin promotes Tiam1-mediated Rac activation during TJ assembly. We therefore compared Rac activity levels in cells expressing Tiam1-HA-WT, -KETDI or -DH* either maintained in high-calcium medium (HCM) or at 60 min following CS. In parental and Tiam1-HA-WT-expressing MDCKII cells Rac activity at 60 min following CS is induced to levels similar to HCM (Supplementary Fig. S4b and Fig. 4d ). In contrast, Tiam1-HA-KETDI-expressing cells showed reduced Rac activity at 60 min following CS (Fig. 4d) , which was significantly lower than in Tiam1-HA-WT-expressing cells (Fig. 4e) . Cells expressing Tiam1-HA-DH* had low Rac activity under both HCM and CS conditions (Fig. 4d) .
We next investigated whether β2-syntrophin knockdown affects Rac activity. Control and β2-syntrophin knockdown cells had comparable levels of Rac activity in HCM (Fig. 4f,g ). However, β2-syntrophin knockdown cells had reduced CS-induced Rac activation (Fig. 4h,i) , consistent with reduced Tiam1 activity because Tiam1 is also required for CS-induced Rac activation (Fig. 4j,k) . Importantly, β2-syntrophin knockdown did not increase the endogenous Tiam1-Par-3 interaction at 60 min following CS ( Supplementary Fig. S4c,d ), excluding the possibility that the Rac activation defects are due to an increase in the inhibitory Par-3-Tiam1 interaction 8 . We next analysed the effect of inhibiting the Tiam1-β2-syntrophin interaction on CS-induced Rac activation. Expression of the Tiam1 fragment KETDI-44 reduced the endogenous interaction (Fig. 4l) . Inducible KETDI-44 expression inhibited CS-induced Rac activation (Fig. 4m,n) , providing further evidence that β2-syntrophin promotes CS-induced Rac activation through binding Tiam1. Furthermore, we observed β2-syntrophin, along with E-cadherin and Par-3, localizing to cell-cell junctions at 60 min after CS ( Supplementary  Fig. S4e ). Together, these results suggest that β2-syntrophin promotes Tiam1-Rac activity at developing cell-cell junctions in MDCKII cells.
β2-syntrophin and Par-3 localize differently along the apicobasal axis
Initially it seemed counterintuitive that β2-syntrophin, an apparent positive regulator of TJ assembly, would promote Tiam1-Rac activity, an apparent negative regulator of TJ assembly. However, the contribution of Tiam1 to CS-induced Rac activation (Fig. 4j,k) indicates also a positive role during TJ assembly. To rationalize our data, and considering the inhibitory effect of Par-3 on Tiam1 during TJ assembly 8 , we postulated that both inhibitors and activators of Tiam1-Rac control TJ assembly. We reasoned that β2-syntrophin and Par-3 localize differently at cell-cell junctions, thereby spatially regulating Tiam1-Rac activity, which might in turn drive optimal TJ assembly. To investigate this, we analysed Par-3, β2-syntrophin and Tiam1 localizations along the apicobasal axis of MDCKII cells. We found that β2-syntrophin localizes more basally than Par-3, although with some overlap (Fig. 5a,b) . Quantifying staining intensities at individual junctions confirmed the differential localizations of Par-3 and β2-syntrophin (Fig. 5c,d ), and revealed that although Tiam1 and Par-3 overlap, the peak of Tiam1 expression was below that of Par-3 ( Fig. 5c ). In β2-syntrophin knockdown cells, although both Tiam1 and Par-3 still localized to cell-cell junctions, we observed a significant shift in Tiam1 localization in the apical direction relative to Par-3 ( Fig. 5e-g ). It is possible that β2-syntrophin promotes TJ assembly through maintaining correct Tiam1 localization along the apicobasal axis, in addition to regulating Tiam1 activity. Staining for the AJ marker E-cadherin revealed that both β2-syntrophin and Tiam1 are present at AJs with low levels of Par-3 (Fig. 5h,i and Supplementary Fig. S5a,b) . Staining for occludin revealed that Par-3, as anticipated, is mainly present at TJs ( Supplementary Fig.  S5c,d ). These staining results imply the presence of a Par-3-Tiam1 complex at TJs and a separate β2-syntrophin-Tiam1 complex at AJs. Consistent with this, β2-syntrophin overexpression reduced the Tiam1-Par-3 interaction (Fig. 5j,k) , indicative of competition between the two complexes and supporting our conclusion that Tiam1 is regulated by different complexes at distinct cell-cell junction locations. From our immunostaining results, we cannot exclude the possibility of a ternary Tiam1-Par-3-β2-syntrophin complex, although the lack of a detectable Par-3-β2-syntrophin interaction (Supplementary Information S5e) suggests any such complex is transitory or contains only a small proportion of the available proteins.
A Rac activity gradient exists along the apicobasal axis
We next investigated whether there is a gradient of Rac localization and/or activity along the apicobasal axis of developing cell-cell junctions. Immunostaining for endogenous Rac and Par-3 after CS revealed that Rac is localized more basally than Par-3 at cell-cell junctions (Fig. 6a,b) . We verified the Rac antibody for immunostaining using Rac1 knockdown and GFP-Rac1 overexpression (Supplementary Fig. S6a-c) . Quantification of staining intensities at individual junctions confirmed the differential localizations of Par-3 and Rac (Fig. 6c,d ). These results suggested that Rac activity is spatially regulated along the apicobasal axis of cell-cell junctions. To address this directly, we performed FLIM-FRET (fluorescence lifetime imaging microscopy-fluorescence resonance energy transfer) analysis of a Rac biosensor in live MDCKII cells as done previously for Rho (ref. 30) . We generated MDCKII cells expressing a membrane-targeted RFP-GFP variant of the Raichu-Rac FRET reporter 31 and confirmed reporter function by performing FLIM-FRET analysis before and after treatment with hepatocyte growth factor (HGF), a known stimulator of Rac activity ( Supplementary Fig. S6d ). Next, we performed FLIM-FRET analysis after CS in cells expressing either Raichu-Rac or membrane-targeted GFP control. We measured average fluorescence lifetimes across individual cell-cell junctions at 0.5 µm steps along the z axis and compared average lifetimes at apical junctional positions (TJs) with those 1 µm below (subapical junctions). We observed no significant lifetime changes in control GFP cells ( Supplementary Fig. S6e,f) . Notably, we observed significantly reduced fluorescence lifetimes of Raichu-Rac, and therefore increased Rac activity, at subapical junctions when compared with apical junctions (Supplementary Fig. S6g,h ). These data confirmed that changes in Rac staining intensity correlate with changes in Rac activity.
Our data demonstrate the existence of an apicobasal Rac activity gradient at cell-cell junctions and we propose that β2-syntrophin and Par-3 are important determinants through their differential regulation of Tiam1 activity. To directly show that β2-syntrophin contributes to the gradient, we analysed Rac localization after CS in β2-syntrophin knockdown cells. Rac was less separated from Par-3 in β2-syntrophin knockdown cells (Fig. 6e,f ) compared with controls ( Fig. 6a-d) . Quantification revealed a significant shift of Rac in the apical direction relative to Par-3 (Fig. 6g) , possibly as a consequence of shifted Tiam1 (Fig. 5g) . We next performed FLIM-FRET analysis after CS in non-targeting RNA-mediated interference (RNAi) and β2-syntrophin knockdown Raichu-Rac-expressing MDCKII cells ( Supplementary  Fig. S6i ). We observed significantly reduced fluorescence lifetimes at subapical junctions when compared with apical junctions in non-targeting RNAi cells (Fig. 6h,i) , consistent with the results above ( Supplementary Fig. S6g,h ), whereas we found no significant lifetime changes in β2-syntrophin knockdown cells (Fig. 6h,i) . These results together with our immunostaining data show that the Rac gradient is diminished in β2-syntrophin knockdown cells. We next investigated the effect of Tiam1 knockdown on the Rac activity gradient using FLIM-FRET analysis. We found significantly reduced fluorescence lifetimes at subapical compared with apical junctions in Tiam1 knockdown cells, similar to what was found for the controls ( Supplementary Fig. S6i-k) . This indicates that a Rac activity gradient can still be formed in Tiam1 knockdown cells, consistent with their ability to form TJs (Fig. 3a,c) . However, we cannot rule out changes to the steepness of the Rac gradient in Tiam1 knockdown cells, which may account for their slightly enhanced CS-induced TER development (Fig. 3a,c) . In these cells, compensatory mechanisms may exist to differentially regulate apicobasal Rac activity. Alternatively, residual Tiam1 may be sufficient to generate a gradient of Rac activity.
Spatial regulation of Rac activity is important for TJ assembly and polarity
To assess the importance of the Rac activity gradient for TJ assembly, we analysed the effect of targeting constitutively active Rac1 (Rac1-V12) to TJs on CS-induced TER development. We used the GBP (GFP-binding protein) targeting system [32] [33] [34] [35] to force an interaction between occludin and Rac1-V12 (Fig. 7a) . We confirmed that GBP-tagged occludin and GFP-tagged Rac1-V12 co-expressed in MDCKII cells interact ( Supplementary Fig. S7a ), resulting in their co-localization at cell-cell junctions (Fig. 7b) . MDCKII cells expressing GBP-occludin alone, GFP-Rac1-V12 alone or GBP-occludin with GFP, GFP-Rac1-V12 or GFP-Rac1-WT were generated. GFP-Rac1-V12 and GFP-Rac1-WT were expressed at levels lower than endogenous Rac ( Supplementary  Fig. S7b,c) to minimize adverse effects of overexpression. Whereas targeting Rac1-V12 to TJs was anticipated to disrupt the Rac activity gradient, Rac1-WT was expected to be less disruptive owing to the low abundance of Rac activators apically. Cells expressing GBP-occludin with GFP-Rac1-V12 had reduced CS-induced TER development indicating TJ assembly defects compared with all controls, including cells expressing GBP-occludin with GFP-Rac1-WT (Fig. 7c) .
As TJ assembly and apical lumen formation are tightly connected 8, [36] [37] [38] , we reasoned that disrupting the Rac activity gradient may perturb apical lumen formation. Cells expressing GBP-occludin with GFP-Rac1-V12 produced more multi-lumen cysts compared with controls when grown in collagen I matrix (Fig. 7d,e) , indicative of impaired apicobasal polarity 39 . Expression of Rac1-V12 alone did not affect cyst development ( Supplementary Fig. S7d,e) . These results suggest that the apicobasal Rac activity gradient at cell-cell junctions regulates TJ assembly and the establishment of apicobasal polarity.
β2-syntrophin regulates polarity and is a potential tumour suppressor in the human prostate
The above results suggest that deregulation of the Rac activity gradient can disrupt TJ integrity and apicobasal polarity, potentially promoting cell proliferation and tumour formation 2, 4, 7, [40] [41] [42] . Therefore, we predicted that β2-syntrophin loss from cell-cell adhesions would disrupt apicobasal polarity and promote tumorigenesis. To address this, we first investigated whether β2-syntrophin regulates apical lumen formation. β2-syntrophin knockdown cells produced mostly multi-lumen cysts (Fig. 8a,b and Supplementary Fig. S8a ), consistent with our results for Rac1-V12 targeted to TJs (Fig. 7d,e) .
Membrane-localized β2-syntrophin has been documented in normal prostate tissue (http://www.proteinatlas.org/ENSG00000168807/ normal). Moreover, Tiam1 overexpression correlates with poor prognosis of human prostate cancer 43 . Furthermore, Rac expression has been observed in healthy prostate tissue and increased Rac expression correlates with prostate cancer progression 44, 45 . We therefore reasoned that the β2-syntrophin-Tiam1-Rac signalling pathway may be deregulated in human prostate cancer. We stained a prostate cancer tissue microarray (TMA) with an anti-β2-syntrophin antibody and scored its expression levels in both malignant and pre-malignant areas (Supplementary Table S2 ). β2-syntrophin expression was frequently reduced in malignant when compared with pre-malignant areas in the same tumour section ( Supplementary Fig. S8b,c and Tables S2 and S3) . However, no significant correlation was found between malignant expression and primary Gleason scores ( Supplementary Fig. S8d ), indicating that β2-syntrophin downregulation is an early event in prostate cancer pathogenesis.
Subsequently, we scored subcellular localization of β2-syntrophin in malignant areas. Membrane β2-syntrophin intensity scores were obtained by combining the expression and localization scores (Supplementary Table S2 ). We found a significant negative correlation between membrane β2-syntrophin intensity and primary Gleason score ( Supplementary Fig. S8e ), revealing that β2-syntrophin is frequently lost from cell-cell adhesions during prostate cancer progression (Supplementary Fig. S8f ). Performing classification regression tree analyses 46 to divide the membrane intensity scores into weak and strong subgroups revealed a significant association between membrane β2-syntrophin intensity and BCR (time to biochemical recurrence) free time ( Supplementary Fig. S8g ), indicating that patients showing reduced β2-syntrophin levels at cell-cell adhesions are more likely to relapse.
DISCUSSION
We have shown that β2-syntrophin, and associated utrophindystrobrevin-β, interact with an internal PBM on Tiam1-a rare mode of PDZ recognition [47] [48] [49] [50] [51] [52] . We infer that the differential effects of β2-syntrophin and Par-3 on Tiam1-Rac activity, in conjunction with their differential but also overlapping localizations, enable them to promote an apicobasal Rac activity gradient at cell-cell junctions (see models; Fig. 8c,d) , which is required for optimal establishment of TJs and apicobasal polarity.
Our findings support those of ref. 53 , in which the data implied that differential apicobasal Rac activity exists in Drosophila columnar epithelia. Here, we have directly visualized an apicobasal Rac activity gradient in mammalian epithelial cells and relate it to TJ formation and apical lumen formation. Our results also have parallels with those of ref. 54 , which demonstrated low apical Rac activity in MDCKII cysts. The β2-syntrophin-Tiam1-Rac pathway might also regulate apicobasal polarity by alternative means: Tiam1, Rac and the dystroglycan-Par-1b complex of which syntrophin is a part all regulate laminin deposition, which is important for apicobasal polarity [55] [56] [57] . Our data enhance our understanding of tumorigenesis. We propose that deregulation of β2-syntrophin, Par-3 or Tiam1 would disrupt the Rac activity gradient, and in turn disrupt TJs and apicobasal polarity, promoting tumorigenesis 2,4,7,40-42 . In agreement is our finding that increased Tiam1-Rac activity impedes TJ assembly and the findings of ref. 54 showing that Tiam1 overexpression at the entire plasma membrane disrupts apicobasal polarity. Moreover, Tiam1 overexpression occurs in many human tumours 43, [58] [59] [60] [61] [62] [63] and correlates with prostate cancer progression 39 . Our TMA data suggest that reduced membrane-associated β2-syntrophin is another mechanism by which Tiam1-Rac signalling at cell-cell junctions is deregulated and highlight the potential of β2-syntrophin as a biomarker for prostate cancer progression and prognosis. Loss-of-function mutations reported for utrophin could be another mechanism 64 . The coordinated action of multiple protein complexes is a wellestablished mechanism of regulation of cell-cell adhesion and polarity 65 . Our data show that cooperation between the Tiam1-β2-syntrophin-utrophin-dystrobrevin-β and Tiam1-Par-3 complexes generates a finely tuned spatial distribution of Rac activity at cell-cell junctions, controlling TJ formation and apicobasal polarity. This may explain previously reported cell-cell adhesion defects following either global Rac activation or inhibition (see ref. 7 for a review).
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary Information is available in the online version of the paper

METHODS
Antibodies.
The primary antibodies used in this study are shown in Supplementary 22) . PH-CC-EX-HA was a gift from J. Collard (The Netherlands Cancer Institute, The Netherlands). C196-HA-WT in pcDNA3.1 was generated by PCR from Tiam1-HA-WT. Tiam1-KETDI constructs were generated by deletion of KET-I residues using QuikChange mutagenesis (Stratagene). KETDI-19, KETDI-27 and KETDI-44 in pcDNA3.1 were generated by PCR from C196-HA-WT. pRetro-X-Tight-Pur-Tiam1-HA-WT, -KETDI and -DH* were generated by ligating corresponding fragments into pRetroX-Tight-Pur (Clontech). The tetracycline-inducible shRNA system has been described previously 16 . shRNA sequences are shown in Supplementary Table S5 . Constitutive RNAi plasmids were generated by ligating sequences into pRetroSuper-Puro (gift from N. Divecha, The Paterson Institute for Cancer Research, UK, as was pRetroSuper-Rac1shRNA). The following β2-syntrophin plasmids 25 : GFP-Syn-FL, GFP-Syn-PDZ, GFP-Syn-PH1ab, GFP-Syn-PH2 and GFP-Syn-SU, were gifts from S. Froehner (University of Washington, USA). β2-syntrophin-rescue (resistant to β2-syntrophin RNAi#1) was generated by mutating GFP-Syn-FL and subsequently ligating into pcDNA4/TO. The RFP-GFP-Raichu-Rac-FRET-reporter plasmid was generated by replacing PKN-BD and RhoA in the RFP-GFP-RhoA-FRET-reporter plasmid 30 with PAK1-BD and Rac1 from pRaichuRac1 (ref. 31 ). LZRS-GBP-Pk-occludin-Zeo was generated from TOPO-GBP-Pk (gift from H. Leonhardt, Ludwig Maximilians University, Germany) and GFP-occludin (gift from A. Reijerkerk, VU University Medical Center, The Netherlands). pEGFP-Rac1-V12 and pEGFP-Rac1-WT were gifts from F. Sanchez-Madrid (Hospital de la Princesa, Spain). pEGFP-F and pEGFP-C1 plasmids were from Clontech. Glo-myc was from A. Hurlstone (University of Manchester, UK).
Cell culture. Mouse embryonic fibroblast (MEF), MDCKII and HEK293T cells
were maintained in DMEM (Invitrogen) with 10% FBS (GIBCO) or 10% tetracycline-free FBS (Autogen Bioclear) and supplemented with the appropriate antibiotics (Zeocin, 0.25 mg ml −1 , Invitrogen; G418, 1 mg ml −1 , Sigma; puromycin, 2 µg ml −1 , Sigma). MEFs were also supplemented with 0.1 mM 2-mercaptoethanol (GIBCO). Selection was withdrawn for experiments.
Generation of cell lines. Retroviral transduction was performed as previously described 11 and transfection with Fugene-6 (Roche) or TransIT-LT1 (Mirus) was performed according to the Manufacturers' instructions, followed by appropriate antibiotic selection.
Cell treatment. For inducible expression, cells were treated with doxycycline
(1 µg ml −1 for confluent cells, 0.2 µg ml −1 for subconfluent cells) for at least three days before analysis. Cells were treated with HGF (10 ng ml −1 ; R&D Systems) following 18 h serum-starvation in DMEM containing 0.1% FBS.
Calcium switch. On day 0, cells were plated at confluency on Transwell filters (TER and immunofluorescence microscopy, 5×10 5 cells per filter; 3460, Corning), 6-well plates (Rac activity assays, 2 × 10 6 cells per well) or 35-mm glass-bottomed dishes (FLIM-FRET analysis, 2 × 10 6 cells per dish; MatTEK Corporation). Medium was changed on day 1. On day 3, monolayers were washed three times with PBS, and then incubated in low-calcium medium (LCM; MEM Eagle, Sigma, supplemented with: l-glutamine; 5% (v/v) dialysed FBS, GIBCO; and 0.02 mM CaCl 2 ) for 18 h. Calcium was added back to 1.8 mM, either by replacing LCM with HCM (LCM supplemented with 1.8 mM CaCl 2 for TER and immunofluorescence microscopy; Leibovitz's L-15 medium, GIBCO, containing 5% FBS for FLIM-FRET), or adding back CaCl 2 (for Rac activity assays).
Transepithelial electrical resistance (TER).
Cells were plated onto Transwell filters and TER was measured using an EVOM2 epithelial voltohmmeter with STX-2 electrodes (World Precision Instruments). Background resistance from a blank filter was subtracted, and resistance was normalized to filter area.
Immunofluorescence microscopy. Except for cysts, cells were grown on
Transwell filters and fixed with either: 100% ice-cold methanol, 5 min, −20 • C (occludin, syntrophin, Tiam1, Par-3 and E-cadherin); 3.7% formaldehyde, 20 min, room temperature (β-catenin); or 10% TCA, 15 min, room temperature (Rac and Par-3). TCA-fixed cells were washed three times with 30 mM glycine/PBS and then incubated with 3% BSA in 0.1% Triton/PBS for 1 h before antibody steps 11 .
Immunostained filters were mounted onto slides in mounting medium (Prolong Antifade, Molecular Probes). Microscopy. The spinning-disc confocal microscope was based around an Olympus IX81, using the Sedat filter set (Chroma, 89000), an array of imaging lasers (406, 488, 548, 645 nm) and an apo ×100 1.45 NA oil objective. The low-light microscope was based around a Zeiss Axiovert 200M, with an Andor iXon DU888+ camera, a 300 W xenon light source, using the Sedat filter set, and a Zeiss alpha plan ×100 1.45 NA oil objective. The time-lapse microscope was based around a Zeiss Axiovert 200M, with a Roper Coolsnap HQ camera and a Zeiss alpha plan Fluar ×10 1.45 NA objective, using white light LED for illumination. The macro-confocal microscope was based around a Leica TCS LSI using a Leica plan apo ×5 0.50 NA objective, an array of solid-state imaging lasers (488, 532 and 635 nm) and an ultrahigh dynamic photomultiplier. Images were captured using Metamorph software (Molecular Devices) or Leica proprietary imaging software and were deconvoluted where necessary using Huygens software (SVI). Numbers of intact junctions were quantified from images acquired on the low-light microscope. The number of intact occludin-stained junctions as a ratio of total nuclei was calculated. Rac, Par-3, syntrophin, and Tiam1 staining intensities were quantified from images acquired on the spinning-disc confocal microscope, by manually drawing around junctions at each z step and recording average pixel intensities using ImageJ software (NIH). Background readings from equivalent regions adjacent to junctions were subtracted. Apical junctional positions were defined as the z steps where the apical Par-3 staining intensity was closest to 0.8.
Cysts. Base layers (250
FLIM-FRET analysis. FRET was measured using frequency-domain FLIM on a
Nikon Eclipse TE 2000-U microscope with a Lambert Instruments LIFA attachment. We used a Yokogawa CSU 22 confocal scanner unit and a ×100 1.4 NA oil objective mounted on a piezo z drive (Nano-Drive, Mad City Labs Inc) to image at different z positions. A 488 nm laser modulated at 40 mHz (60 mW, Deepstar, Omicron) was used to enable measurement of fluorescence lifetimes in the frequency domain. Lifetime images were acquired at 500 nm z steps. Standard halogen illumination together with a GFP-filterblock (470/40X, T495LP, 525/50M) enabled visualization of probe expression. Erythrosin B (1 mg ml −1 ) was used as a reference standard (0.086 ns). Donor lifetime at cell-cell junctions was analysed by manually drawing around junctions at each z step using the FLIM software (Version 1.2.1, Lambert Instruments). Apical junctions were identified as the first z step at which junction GFP was focused and subapical junctions were assumed to be 1 µm below.
Protein analysis. Cells were lysed in immunoprecipitation lysis buffer (50 mM
Tris-HCl, at pH 7.5, 150 mM NaCl, 1% (v/v) Triton-X-100, 10% (v/v) glycerol, 2 mM EDTA, 25 mM NaF and 2 mM NaH 2 PO 4 ) containing protease and phosphatase inhibitor cocktails (Sigma). Immunoprecipitation and immunoblotting were performed as described previously 11 , except GFP-Trap beads (Chromotech) were used for some GFP-β2-syntrophin immunoprecipitations. Immunoblot band intensities were quantified using Genetools software (SynGene).
Tandem affinity purification (TAP) and mass spectrometry. Tiam1 knockout
MEFs expressing Tiam1-HA-CTAP or HA-CTAP were cultured in 20-40 500 cm 2 dishes (plating 10 7 cells per dish) for two days. TAP purifications were performed as previously described 22 . Samples were run on one-dimensional gels (Nupage 4-12%), and then lanes were manually cut into 40 bands. Bands were processed robotically using a ProGest instrument. Digested gel slices (30 µl) were analysed using nanoliquid chromatography-tandem mass spectrometry on a LTQ-Orbitrap-XL or
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LTQ tandem mass spectrometer (ThermoFisher). Product ion data were searched against the combined forward and reverse IPI mouse v3.29 protein database using the Mascot search engine v2.0.04 (Matrix Science) through Mascot Daemon v2.0.0. Mascot search result flat files (DAT) were parsed to the Scaffold program (Proteome Software). Criteria for accepting protein identifications were determined by calculating the false discovery rates from the concatenated forward/reverse database, resulting in the following cutoff values: 90% protein, 50% peptide level probability, and minimum two unique peptides per protein. These criteria resulted in false discovery rates of <0.5% at the protein level for each data set.
Rac activity assay. Rac activity was assayed as previously described 22 .
Hanging-drop assay. Drops (30 µl) of cells (10 6 cells ml −1 ) were hung from 24-well plate lids above H 2 O and allowed to aggregate for 0-3 h at 37 • C. Drops were passed through 20 µl pipette tips 10 times before imaging. Images were captured of 10-12 fields per drop using the time-lapse microscope at ×10 magnification. At least 2 drops were analysed per experiment. Aggregate areas were measured using ImageJ.
Cell-dissociation assay. Cell-dissociation assays were performed on MDCKII colonies as previously described 11 .
Immunohistochemical analysis. The prostate cancer TMA included tumour specimens from 122 patients and has been described elsewhere 67 . After removing patients who received neoadjuvant radiation and hormonal therapy, missing cores and cores with no cancer, 74 patients remained for analyses. Scorings were verified by two independent observers. Immunohistochemistry for β2-syntrophin and classification tree analyses were performed as described previously 46, 68 . BCR was defined as a blood prostate-specific antigen concentration of ≥0.2 ng ml −1 and a subsequent confirmatory value.
Statistical analysis. The specific statistical tests used are indicated in the figure legends alongside the P values. KETDI-44 Figure S9 Uncropped image blots. Table 1 Mass spectrometry spectral count data for identified proteins from control (Con) and Tiam1 TAP purifications. Table 2 Scoring data from β2-syntrophin immunostained cores of prostate tumours mounted in duplicates on a TMA. The table shows scorings of expression of β2-syntrophin in malignant areas of the tumours (malignant β2-syntrophin expression), localisation of β2-syntrophin in malignant areas of the tumours (malignant β2-syntrophin localisation) and expression of β2-syntrophin in pre-malignant areas of the tumours (pre-malignant β2-syntrophin expression), alongside the corresponding Primary Gleason scores (grade of the predominant malignant population) and BCR free time (time to biochemical recurrence) data. β2-syntrophin expression was scored using arbitrary units from 0-3, with 0 representing no staining, 1 as weak staining, 2 as moderate staining and 3 as strong staining. β2-syntrophin localisation was scored from 1-3, with 1 representing predominantly cytoplasmic, 2 disturbed membrane localisation and/ or increased cytoplasmic, and 3 predominantly membrane localisation. To gain a more accurate score of the intensity of β2-syntrophin expression in the membrane in malignant areas of the tumours we multiplied the malignant β2-syntrophin expression and localisation scores obtaining scores in the range 0-9 (malignant membrane β2-syntrophin intensity). Table 3 The number of prostate tumours with malignant β2-syntrophin expression scores at ratios 0.75-1 or <0.75 of their corresponding pre-malignant expression scores. 
